Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Observation × Other solid neoplasm × Clear all

Phase

Phase NA 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9 Genitourinary 7 Head & Neck 6 Thoracic 4 Lymphoid 4 Other hematologic neoplasm 3 Gynecologic 3 Breast 3 Plasma cell 2 CNS 2 Other solid neoplasm 1 Other neoplasm 1 Other 1 Endocrine 1 Dermatologic 1

Conditions

Retinoblastoma 1

Interventions

Cisplatin 39 Pemetrexed 29 Carboplatin 23 Nivolumab 19 Gemcitabine 18 pembrolizumab 16 atezolizumab 13 Ipilimumab 10 Injections 10 Docetaxel 10 Cyclophosphamide 10 Bevacizumab 10 Radiotherapy 9 Oxaliplatin 9 Etoposide 9 tislelizumab 8 durvalumab 8 Specimen Handling 8 Paclitaxel 8 Filgrastim 8 Capecitabine 8 tremelimumab 7 lenvatinib 7 olaparib 6 niraparib 6 Vinorelbine 6 Vincristine 6 Immune Checkpoint Inhibitors 6 Biopsy 6 toripalimab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02870907 2026-01-07

RB SFCE 09

Institut Curie

Phase 2 Active not recruiting

Other solid neoplasm

Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡